159847-81-1

Basic information

• Product Name: METHYL 2-AMINO-5-CYANOBENZOATE
• Synonyms: METHYL 2-AMINO-5-CYANOBENZOATE;2-Amino-5-cyanobenzoic acid methyl ester;Methyl 2-amino-5-cyanobenzoate≥ 97% (HPLC)
• CAS NO: 159847-81-1
• Molecular Formula: C₉H₈N₂O₂
• Molecular Weight: 176.17202
• Mol File: 159847-81-1.mol

Chemical Properties

• Boiling Point: 334.08°C at 760 mmHg
• Flash Point: 155.846°C
• Appearance: /
• Density: 1.262g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.574
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 0.95±0.10(Predicted)
• CAS DataBase Reference: METHYL 2-AMINO-5-CYANOBENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 2-AMINO-5-CYANOBENZOATE(159847-81-1)
• EPA Substance Registry System: METHYL 2-AMINO-5-CYANOBENZOATE(159847-81-1)

Safety Data

• Hazardous Substances Data: 159847-81-1(Hazardous Substances Data)

Usage

Chemical Properties

Pale yellow crystalline powder

InChI:InChI=1/C9H8N2O2/c1-13-9(12)7-4-6(5-10)2-3-8(7)11/h2-4H,11H2,1H3

Upstream product

• 52727-57-8 5-bromo-2-aminobenzoic acid methyl ester 
• 5794-88-7 5-Bromo-2-aminobenzoic acid 
• 134-20-3 2-carbomethoxyaniline 
• 67-56-1 methanol 
• 201230-82-2 carbon monoxide 
• 33348-34-4 4-amino-3-iodobenzonitrile 
• 99767-45-0 2-amino-5-cyanobenzoic acid 
• 544-92-3 copper(I) cyanide 
• 615-57-6 2,4-dibromo-aniline 
• 19619-22-8 2,4-dicyanoaniline 

Downstream Products

• 99767-45-0 2-amino-5-cyanobenzoic acid 
• 1428482-14-7 2-bromo-5-thiocarbamoyl-benzoic acid methyl ester 
• 1428482-15-8 2-bromo-5-[4-(3,4-dichloro-phenyl)-thiazol-2-yl]-benzoic acid methyl ester 
• 1428482-16-9 4-[4-(3,4-dichloro-phenyl)-thiazol-2-yl]-biphenyl-2,4'-dicarboxylic acid 4'-tert-butyl ester 2-methyl ester 
• 1428482-17-0 4-[4-(3,4-dichloro-phenyl)-thiazol-2-yl]-biphenyl-2,4'-dicarboxylic acid 2-methyl ester 
• 1428482-18-1 4-[4-(4-fluoro-phenyl)-thiazol-2-yl]-2'-nitro-biphenyl-2-carboxylic acid methyl ester 
• 1428480-59-4 4-[4-(4-fluoro-phenyl)-thiazol-2-yl]-2'-nitro-biphenyl-2-carboxylic acid 
• 1428480-62-9 4-[4-(3,4-dichloro-phenyl)-thiazol-2-yl]-2'-nitro-5'-trifluoromethyl-biphenyl-2-carboxylic acid 
• 1428480-73-2 4-[4-(3,4-dichloro-phenyl)-thiazol-2-yl]-2'-nitro-biphenyl-2-carboxylic acid 
• 1428480-75-4 4-[4-(3-chloro-4-fluoro-phenyl)-thiazol-2-yl]-2'-nitro-biphenyl-2-carboxylic acid 
• 1428482-20-5 4-[4-(3-chloro-4-fluoro-phenyl)-thiazol-2-yl]-2'-nitro-biphenyl-2-carboxylic acid methyl ester 
• 1428480-90-3 4-[4-(4-methoxy-phenyl)-thiazol-2-yl]-2'-nitro-biphenyl-2-carboxylic acid 
• 1428482-21-6 4-[4-(4-methoxy-phenyl)-thiazol-2-yl]-2'-nitro-biphenyl-2-carboxylic acid methyl ester 
• 1428481-04-2 4-[4-(3,4-dichloro-phenyl)-thiazol-2-yl]-4'-nitro-biphenyl-2-carboxylic acid 

Relevant articles and documents

INHIBITORS OF ENCEPHALITIC ALPHAVIRUSES

Compounds of Formula I and Formula II: pharmaceutical compositions containing them, and use of the compounds as active ingredients to treat infection with alphavirus.

One-Pot Synthesis and Conformational Analysis of Six-Membered Cyclic Iodonium Salts

Two one-pot procedures for the construction of carbon-bridged diaryliodonium triflates and tetrafluoroborates are described. Strong Br?nsted acids enable the effective Friedel-Crafts alkylation with diversely substituted o-iodobenzyl alcohol derivatives, providing diphenylmethane scaffolds, which are subsequently oxidized and cyclized to the corresponding dibenzo[b,e]iodininium salts. Based on NMR investigations and density functional theory (DFT) calculations, we could verify the so-far-undescribed existence of two stable isomers in cyclic iodonium salts substituted with aliphatic side chains in the carbon bridge.

Triketone-based compound preparation method

The invention relates to the field of preparation of pesticides, and discloses a triketone-based compound preparation method, wherein the triketone-based compound has a structure represented by a formula (1). The method comprises that 1) a compound represented by a formula (2), 1,3-cyclohexanedione and CO are subjected to a reaction in the presence of a first catalyst under an alkali condition toobtain a product represented by a formula (3); and 2) the product represented by the formula (3) contacts a second catalyst and an alkali substance under a rearrangement reaction condition to obtain the triketone-based compound represented by the formula (1). According to the present invention, with the method, the triketone-based compound can be obtained in the low-cost and high-yield manner; andthe purity of the triketone-based compound obtained through the method is high. The formulas (1), (2) and (3) are defined in the specification.

Identification of a Novel 1,2,3,4-Tetrahydrobenzo[b][1,6]naphthyridine Analogue as a Potent Phosphodiesterase 5 Inhibitor with Improved Aqueous Solubility for the Treatment of Alzheimer's Disease

Phosphodiesterase 5 (PDE5) hydrolyzes cyclic guanosine monophosphate (cGMP) leading to increased levels of the cAMP response element binding protein (CREB), a transcriptional factor involved with learning and memory processes. We previously reported poten

6-SUBSTITUTED QUINAZOLINONE INHIBITORS

The present technology relates to compounds and compositions of Formulas I-III and methods using such compounds. The compounds and compositions described herein may be used in the treatment or prophylaxis of diseases associated with an alphavirus, for exa

Development of (E)-2-((1,4-Dimethylpiperazin-2-ylidene)amino)-5-nitro-N-phenylbenzamide, ML336: Novel 2-Amidinophenylbenzamides as Potent Inhibitors of Venezuelan Equine Encephalitis Virus

Venezuelan equine encephalitis virus (VEEV) is an emerging pathogenic alphavirus that can cause significant disease in humans. Given the absence of therapeutic options available and the significance of VEEV as a weaponized agent, an optimization effort wa

Discovery of novel bacterial RNA polymerase inhibitors: Pharmacophore-based virtual screening and hit optimization

The bacterial RNA polymerase (RNAP) is a validated target for broad spectrum antibiotics. However, the efficiency of drugs is reduced by resistance. To discover novel RNAP inhibitors, a pharmacophore based on the alignment of described inhibitors was used for virtual screening. In an optimization process of hit compounds, novel derivatives with improved in vitro potency were discovered. Investigations concerning the molecular mechanism of RNAP inhibition reveal that they prevent the protein-protein interaction (PPI) between σ70 and the RNAP core enzyme. Besides of reducing RNA formation, the inhibitors were shown to interfere with bacterial lipid biosynthesis. The compounds were active against Gram-positive pathogens and revealed significantly lower resistance frequencies compared to clinically used rifampicin.

BENZOIC ACID DERIVATIVES

There are disclosed are compounds of the formula: wherein R1 and R2 are as disclosed herein, which are eIF4E inhibitors useful in the treatment of cancers. Also disclosed are compositions comprising the compounds, as well as methods of treating cancer using the compounds.

Bioorthogonal approach to identify unsuspected drug targets in live cells

A proteomics method to pull down secondary drug targets from live cells is described. The drug of interest is modified with trans-cyclooctene (TCO) and incubated with live cells. Upon cell lysis, the modified drug bound to the protein is pulled down using magnetic beads decorated with a cleavable tetrazine-modified linker. Samples are then run on an SDS-PAGE gel and isolated bands are submitted for mass spectrometry analysis to identify drug targets. Copyright

QUINOLINONE DERIVATIVES AS INHIBITORS OF C-FMS KINASE

The invention is directed to compounds of Formulae I and II: (I) (II) wherein R1, R2, R3, R5, R6, Y1, Y2, Y3, Y4 and X are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.